Table 2. Completed clinical trials evaluating the role of MSC in the management of osteoarthritis knee with published results.

Sl. No.	Author	NCT No.	Year	Country	MSC source	Cell density	Total patients	Follow up	Clinical trial phase
1	de Girolamo et al.	NCT01485198	2010	Mexico	Autologous hematopoietic stem cells from bone marrow	10 mL BMAC	61	6 months	I
2	Taghiyar et al.	NCT00850187	2012	Iran	Autologous cultured BM-MSCs	–	6	12 months	I
3	Emadedin et al.	NCT01207661	2012	Iran	Autologous cultured BM-MSCs	5×105 cells/kg/body weight	6	12 months	I
4	Shadmanfar et al.	NCT01873625	2013	Iran	Autologous BM-MSCs	–	60	6 months	II & III
5	Sheinkop	NCT01601951	2014	USA	Autologous BMAC	–	12	12 months	I
6	Pers YM et al.	NCT01585857	2014	France	Autologous AD-MSCs	2/10/50×106 AD- MSCs	18		I
7	Vives et al.	NCT01227694	2015	Spain	Autologous cultured BM-MSCs	40×106 MSCs	15	12 months	I & II
8	Orozco et al.	NCT01183728	2015	Spain	Autologous BM-MSCs	40×106 MSCs	12	24 months	I & II
9	Orozco et al.	NCT01586312	2015	Spain	Allogenic ex vivo cultured BM-MSCs	40×106 MSCs	30	12 months	I & II
10	Al-Najar et al.	NCT02118519	2016	Jordan	Allogenic in vitro cultured BM-MSCs	61×106±0.6×106 MSCs	13	12 months	II
11	Pham et al.	NCT02142842	2016	Vietnam	Autologous SVF and PRP	SVF—1.0 to 5.0×107 cells	30	18 months	I & II
12	Ghani et al.	NCT01448434	2016	Malaysia	Ex vivo cultured adult allogenic MSCs	–	72	12 months	II
13	Agarwal et al.	NCT01453738	2016	India	Ex vivo cultured allogenic BM-MSCs	25/50/75/150×106 cells	60	12 months	II
14	Royan Institute	NCT01504464	2016	Iran	MSCs	–	40	3 months	II
15	Chen PJ	NCT02291926	2017	China	Human UC-MSCs	2×107 hUC-MSCs	20	12 months	I
16	Camilleri et al. and Shapiro et al.	NCT01931007	2017	USA	Autologous BMAC	5 mL of treated cells + 10 mL platelet poor bone marrow plasma	25	12 months	I
17	Lamo-Espinosaet al.	NCT02123368	2017	Spain	Autologous ex vivo cultured BM-MSCs	10×106 cells	30	12 months	I & II
18	Song et al.	NCT01809769	2017	China	Autologous AD-MSCs	1/2/5×107 cells/3 mL	18	24 months	I & II
19	Bao and Zhang	NCT02162693	2017	China	Autologous in vitroextended AD-MSCs	–	53	12 months	II
20	Lim et al.	NCT01041001	2017	Korea	CARTISTEM allogenic UC-MSCs	Single dose of 500 μL/cm2 containing 2.5×106 cells	102	60 months	III
21	Lim et al.	NCT01626677	2017	Korea	CARTISTEM allogenic UC-MSCs	Single dose of 500 μL/cm2 containing 2.5×106 cells	103	48 months	III
22	Matas and Espinoza	NCT02580695	2018	Chile	Allogenic UC-MSCs	20×106 and 3 mL hyaluronic acid	30	12 months	I & II
23	Ruane	NCT02958267	2018	USA	Autologous BMAC	5–6 mL BMAC	30	12 months	II
24	Cellular Biomedicinegroup	NCT02641860	2018	China	Autologous in vitro extended AD-MSCs	–	22	48 months	I
25	Jas Chahal	NCT02351011	2019	Canada	Autologous MSCs	1/10/50×106 MSCs	12	60 months	I & II
26	Lee WS et al.	NCT02658344	2019	Korea	Autologous AD-MSCs	1×108 cells per 3 mL	24	6 months	II
27	Ho Ki Wai	NCT04326985	2020	Hong Kong	Autologous MSCs	–	20	12 months	I
28	Gary Hieronimus	NCT03337243	2020	USA	Human amniotic membrane and Human umbilical cord & Wharton’s jelly injections	–	60	3 months	I
29	Nature Cell Company	NCT02674399	2020	USA	Autologous AD-MSCs	–	28	24 months	II

BMAC, bone marrow aspirate concentrate; BM-MSCs, bone marrow derived MSCs; AD-MSCs, adipose tissue derived MSCs; UC-MSCs, umbilical cord derived MSCs; PRP, platelet rich plasma; SVF, stromal vascular fraction.